Auxilium Pharmaceuticals Inc agreed to be bought by Endo International Plc for $1.67 billion and terminated its deal to purchase Canadian eye-drug maker QLT Inc.Auxilium accepted Endo's offer of $33.25 per share in cash and stock, almost a month after rebuffing a previous offer of $28.10 per share, saying it significantly undervalued the company.Auxilium shares rose 11 percent in premarket to $33, while Endo shares were down 0.7 percent at $70.50.Endo, whose men's healthcare products include testosterone replacement therapy Aveed, will now get access to Auxilium's drugs to treat a condition which causes painful erections and a disease that affects the ability to properly use one's fingers.
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences. Shares of AUXL fell by 0.57% or $-0.17/share to $29.76. In the past year, the shares have traded as low as $16.36 and as high as $32.89. On average, 1463120 shares of AUXL exchange hands on a given day and today's volume is recorded at 5375140.
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. Shares of QLT fell by 1.09% or $-0.05/share to $4.53. In the past year, the shares have traded as low as $4.45 and as high as $7.90. On average, 3600 shares of QLT.TO exchange hands on a given day and today's volume is recorded at 550.
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. Shares of QLTI fell by 1.22% or $-0.05/share to $4.04. In the past year, the shares have traded as low as $4.00 and as high as $7.10. On average, 138309 shares of QLTI exchange hands on a given day and today's volume is recorded at 45500.
Source
